Ajjai Alva discusses the negative KEYNOTE-361 trial findings for pembrolizumab with or without chemotherapy for treatment-naïve advanced urothelial cancer (6:13).
This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany